JUPITER NEUROSCIENCES, INC.

Jupiter Neurosciences, Inc.

Biotechnology • Healthcare • Jupiter, FL, United States • JUNS (NCM)

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. It is also involved in the development of JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, the company develops JNS115, which is in Phase IIa trial for the treatment of Parkinson's disease. It has a strategic partnership with Zina Biopharmaceuticals, LLC to advance Phase 2a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of Resveratrol (JOTROLTM) in individuals with Parkinson's disease; and with Aquanova AG to develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.

561 406 6154 1001 North US Highway 1, Jupiter, FL 33477, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Jupiter Neurosciences Expands Equity Financing Through SEPA Advances - TipRanks
TipRanks • Dec 23
Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement - Yahoo Finance
Yahoo Finance • Jul 10
Jupiter Neurosciences (NASDAQ: JUNS) wins FDA IND for Phase 2a Parkinson’s trial - Stock Titan
Stock Titan • Nov 5
Jupiter Neurosciences, Inc. Regains Nasdaq Compliance as Stock Price Shows Positive Momentum - Nasdaq
Nasdaq • Jul 10
Jupiter Neurosciences Signs Multiple Material Agreements - TradingView — Track All Markets
TradingView — Track All Markets • Dec 23

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has JUPITER NEUROSCIENCES, INC. had layoffs?
No layoff events have been recorded for JUPITER NEUROSCIENCES, INC. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does JUPITER NEUROSCIENCES, INC. have?
JUPITER NEUROSCIENCES, INC. has approximately 4 employees.
What industry is JUPITER NEUROSCIENCES, INC. in?
JUPITER NEUROSCIENCES, INC. operates in the Biotechnology industry, within the Healthcare sector.
Is JUPITER NEUROSCIENCES, INC. a publicly traded company?
Yes, JUPITER NEUROSCIENCES, INC. is publicly traded under the ticker symbol JUNS on the NCM. The company has a market capitalization of approximately $0.04 billion.
Where is JUPITER NEUROSCIENCES, INC. headquartered?
JUPITER NEUROSCIENCES, INC. is headquartered in Jupiter, FL, United States at 1001 North US Highway 1, Jupiter, FL 33477, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.